INFI - Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc.
1100 Massachusetts Avenue
Floor 4
Cambridge, MA 02138
United States
(617) 453-1000
https://www.infi.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 30
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Ms. Adelene Q. Perkins | Chairman & CEO | 701,51k | N/D | 1960 |
| Dr. Robert Ilaria Jr., M.D. | Chief Medical Officer | 653,8k | N/D | 1961 |
| Dr. Lawrence E. Bloch J.D., M.D. | Treasurer | 513,61k | N/D | 1966 |
| Ms. Melissa Hackel | VP of Fin. | N/D | N/D | N/D |
| Dr. Stephane Peluso Ph.D. | Chief Scientific Officer | N/D | N/D | 1971 |
| Mr. Seth A. Tasker J.D. | Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. | N/D | N/D | 1979 |
Descrizione
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.
Governance aziendale
L'ISS Governance QualityScore di Infinity Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.
